The week in pharma: action, reaction and insight – week to April 5, 2024
By Barbara Obstoj-Cardwell. Editor
Among last week’s news, Switzerland-based Roivant Sciences and partner company Priovant released positive Phase II data for their uveitis candidate brepocitinib. On the M&A front, Danish drugmaker Genmab announced it would acquire privately-held USA-based ProfoundBio for $1.8 billion in cash, gaining access to its antibody-drug conjugate (ADC) Rina-S. Also, US healthcare giant Johnson & Johnson on Friday revealed its intention to acquire cardio-devices leader Shockwave Medical, noting an enterprise value of $13.1 billion. Also of note, the US Food and Drug Administration (FDA) has approved Swiss drugmaker Basilea Pharmaceutica’s antibiotic Zevtera for three indications.
Positive brepocitinib NIU Phase II from Roivant/Priovant
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze